Key Takeaways
- Standalone shines, subsidiaries bleed: Standalone revenue grew 18% YoY with 154 bps EBITDA margin expansion, while consolidated EBITDA margin fell 165 bps to 6.16% as European and Canadian losses dragged.
- H2 ramp-up is inventory-backed: Inventory built up ~40-45% over six months against firm orders, split evenly across BTS and EMS, positioning for back-ended BTS billing and new EMS customer production in Q3.
- Subsidiary exits are now on the clock: Canada divestment is "quite close" to closing, and a strategic decision on the loss-making European business is promised by Q4, with the objective of zero subsidiary losses next financial year.
- Domestic defence pipeline is the thesis: A ₹2,000+ cr three-year BTS order booking target, two new MoUs (GRSE, BEL), and a space-based surveillance pipeline support management's confidence in hitting 30% standalone growth.
- What to watch next quarter: Whether the Canada divestment closes, the pace of domestic BTS order booking in Q3, and any early signal on the European strategic direction.
Standalone vs. Consolidated: A Tale of Two Businesses
- Standalone revenue grew 18% YoY, driven by strong execution in the Build-to-Spec business for domestic defence and space customers.
- Standalone EBITDA margin expanded 154 bps to 11.97%, helped by operational efficiency and a richer mix of high-quality BTS revenue.
- Consolidated EBITDA margin contracted 165 bps to 6.16%, entirely because of losses in international subsidiaries.
- Management focus is squarely on the standalone business, which it calls "really a good story," and it is confident of hitting 30% growth for the full year.
- Consolidated FY26 guidance is maintained: management believes they are likely to not miss the earlier guidance of ~18% top-line growth and 12-13% EBITDA margin, provided domestic orders execute.
Mallavarapu: "The objective is that we clearly would like as much as possible to not have any losses from the subsidiary impacting our overall numbers in the next financial year."
Subsidiary Restructuring: Canada Exit, Europe Review
- Canada divestment is in advanced-stage discussions with a third party; a backup solution exists via the customer or a court-assisted process if that fails.
- Canada timeline is tight: a decision is expected in a few months, by the end of the quarter, and management says things are on track to close in the "very short term."
- Canada loss trajectory improved QoQ, with the Q2 loss lower than Q1's ~₹0.6 crores.
- European subsidiary faces two headwinds: weak macroeconomic conditions and intense ER&D competition in France, plus defence budgets shifting to production contracts while new design and development projects are delayed.
- European strategic review is evaluating long-term options in light of the opportunity in India; a direction is expected by end of Q4.
- European cost actions include restructured bank loans to release cash stress, closure of a bond discount (₹0.1 crore), and operating H1 without additional infusion support.
- European seasonality provides some natural H2 lift: the H1:H2 revenue ratio is typically 45:55 or 46:54 because H1 has reduced working days from May and August holidays.
- H2 subsidiary loss outlook is for a "slightly lesser loss" than H1, a "moderate loss" rather than profits; management declined to give a specific number.
Mallavarapu: "We are quite close to finalizing the divestment of the Canadian subsidiary. Things are on track to close that in the very short term."
Domestic Defence & Space: The Growth Engine
- BTS order booking target is a little over ₹2,000 cr over a three-year period including this year, with very strong order booking expected in Q3 and Q4.
- Space-based surveillance has a reasonably good pipeline, with orders expected to be booked even in the current financial year; the addressable opportunity is ~₹1,000 cr, per an analyst's math.
- Additional satellite constellations are indicated by customers beyond the ~₹300 crore order already in hand.
- Electronic warfare payloads won in the past year are in advanced design finalization, with delivery expected over the next few quarters.
- ISRO CMS-3 GSAT7R program saw delivery of nearly 400 critical modules.
- GRSE MoU covers a navigation system for aircraft onto ships, primarily for military applications; currently only one ship has this system, but it is becoming a requirement for all ships, with orders coming in smaller parts year by year over five years.
- BEL MoU aims to advance indigenous defence electronics across electronic warfare, radar and military communication systems.
- Radar and electronic warfare opportunities are substantial, though timelines carry uncertainties.
- Shipbuilding is a newer area for Centum; the company is exploring more as it goes forward.
- Space export is at a "nascent stage" but evolving rapidly; management is watching how to leverage export opportunities.
H2 Ramp-Up: Inventory, BTS Back-Ending, EMS Production
- Inventory build-up of ~40-45% over the past six months was bought against firm purchase orders or customer forecasts, split equally between BTS and EMS divisions, in anticipation of higher H2 deliveries.
- Payables increased alongside inventory and will get liquidated over time.
- BTS billing is typically back-ended in Q4, an industry pattern that supports the H2 acceleration thesis.
- EMS growth is expected to be very strong this year, with new customer additions now entering production in Q3.
- Standalone H2 numbers are typically higher than H1, and the inventory build supports this pattern.
- Overall standalone growth target is 30% for the full year, with management saying they will "if not strengthen that."
Margins & Financial Health
- Standalone EBITDA margin is expected to land in the 13-15% range for the full year at the standalone level.
- Consolidated margin drag is entirely from subsidiaries; the standalone business is expanding margins through mix and efficiency.
- NABL accreditation for the BTS unit enhances credibility in defence contracts.
- CII recognition as an energy efficient unit for excellence in energy management for 2025.
- Liquidity management in Europe included loan restructuring and operating H1 without additional infusion support.
Mallavarapu: "There will be a slightly lesser loss than we have had in the first half. We don't expect to have profits in the second half of the year. We will have, however, a moderate loss."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Standalone revenue growth | 30% growth for full year | FY26 |
| Standalone EBITDA margin | 13% to 15% range | FY26 |
| Consolidated revenue growth | ~18% top-line growth (maintain earlier guidance) | FY26 |
| Consolidated EBITDA margin | 12% to 13% (maintain earlier guidance) | FY26 |
| Canada divestment decision | Close or decide on divestment path | By end of Q3 FY26 |
| European strategic direction | Decision on strategic options | By end of Q4 FY26 |
| Subsidiary loss elimination | No losses from subsidiaries impacting overall numbers | Next financial year (FY27) |
| BTS order booking | Very strong order booking; ₹2,000+ cr over three years including this year | Q3 and Q4 FY26, through FY28 |
| Space-based surveillance orders | Orders to be booked | Current financial year (FY26) |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Standalone revenue | ₹206 cr, ~18% YoY growth |
| Standalone EBITDA | ~₹25 cr, 36% YoY growth; margin 11.97%, up 154 bps YoY |
| Standalone PAT | ~₹13 cr, 97% YoY increase |
| Consolidated revenue | ₹291 cr, ~12% YoY increase |
| Consolidated EBITDA | ~₹18 cr, 12% YoY decline; margin 6.16%, down 165 bps YoY |
| Consolidated PAT | ₹4 cr, versus loss of ₹30 lakh in Q2 FY25 |
| Standalone H1 FY26 revenue | ₹391 cr, 24% YoY growth |
| Standalone H1 FY26 EBITDA margin | 12.88%, up 338 bps YoY |
| Standalone H1 FY26 PAT | ₹29 cr, 182% YoY growth |
| Consolidated H1 FY26 revenue | ₹564 cr, 12% YoY growth |
| Consolidated H1 FY26 EBITDA margin | 7.22%, up 14 bps YoY |
| Consolidated H1 FY26 PAT | ~₹9 cr, versus loss of ₹4 cr in H1 FY25 |
| Standalone full-year revenue growth guidance | 30% for FY26 |
| Standalone full-year EBITDA margin guidance | 13% to 15% for FY26 |
| Domestic Build-to-Spec order book | ~₹650 cr as of Q2 FY26 |
| EMS order book | ₹763 cr at end of Q2 FY26 |
| Borrowings | ~₹108 cr as of Sep 30, 2025, net of ₹16 cr discounted LCs; ~12% increase |
| Cash balances | ₹136 cr as of Sep 30, 2025, includes ~₹76 cr from QIP proceeds |
| Subsidiary loss (H1 FY26) | ₹21 cr in last six months |
| Inventory increase | ~40–45% over past six months, against firm orders |
| Space-based surveillance addressable opportunity | ~₹1,000 cr |
| Three-year domestic BTS order booking target | a little over ₹2,000 cr |
| GRSE partnership opportunity | ~₹500–₹600 cr over five years |